Evidence map›Paper›PMID 36701211›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes.

Xin Wang, Iris Broce, Yuqi Qiu, Kacie D Deters, Chun Chieh Fan, Anders M Dale, Steven D Edland, Sarah J Banks, Alzheimer's Disease Neuroimaging Initiative

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Xin WangUniversity of California, San Diego, California, USA.
Iris BroceUniversity of California, San Diego, California, USA.
Yuqi QiuEast China Normal University, Shanghai, China.
Kacie D DetersUniversity of California, Los Angeles, California, USA.
Chun Chieh FanUniversity of California, San Diego, California, USA.
Anders M DaleUniversity of California, San Diego, California, USA.
Steven D EdlandUniversity of California, San Diego, California, USA.
Sarah J BanksUniversity of California, San Diego, California, USA.
Alzheimer's Disease Neuroimaging Initiative
University of California, San Diego · USEast China Normal University · CNUniversity of California, Los Angeles · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOUGLAS R GALASKO · 2019 to 2026
$34.9M
Sex-specific cognitive expression and risk in preclinical Alzheimer's diseaseR01AG066088 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BANKS, SARAH · 2019 to 2023
$3.9M
UCSD Leading the Advancement of Underrepresented Neuroscientists for Change (LAUNCH) Faculty Development ProgramR25NS117367 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victoria B Risbrough, Joann Trejo · 2020 to 2026
$1.6M
Novel imaging genetic biomarkers for sporadic frontotemporal dementia through machine learningK01AG070376 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROCE-DIAZ, IRIS J · 2021 to 2025
$528k
NIA NIH HHS K01 AG070376NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG066088NIA NIH HHS U01 AG024904NINDS NIH HHS R25 NS117367
6 · The paper itself

Abstract

introductionIdentifying individuals who are most likely to accumulate tau and exhibit cognitive decline is critical for Alzheimer's disease (AD) clinical trials.

methodsParticipants (N = 235) who were cognitively normal or with mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative were stratified by a cutoff on the polygenic hazard score (PHS) at 65th percentile (above as high-risk group and below as low-risk group). We evaluated the associations between the PHS risk groups and tau positron emission tomography and cognitive decline, respectively. Power analyses estimated the sample size needed for clinical trials to detect differences in tau accumulation or cognitive change.

resultsThe high-risk group showed faster tau accumulation and cognitive decline. Clinical trials using the high-risk group would require a fraction of the sample size as trials without this inclusion criterion. DISCUSSION: Incorporating a PHS inclusion criterion represents a low-cost and accessible way to identify potential participants for AD clinical trials.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersBrainCognitionHumansPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer's diseaseclinical trialspolygenic hazard scoretau positron emission tomography

Identifiers

PMID36701211
PMCPMC10368787
OpenAlexW4318164802

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.